News
At ASCO 2025, Bayer announced new data from recent clinical trials that highlight significant advancements in both prostate ...
Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...
Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...
The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...
Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...
Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...
Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...
Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...
Artificial intelligence specialist Artera has won FDA approval for AI-powered software that can help guide the management of patients diagnosed with localised prostate cancer. ArteraAI Prostate is ...
A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.
Given the labyrinth of patent litigation ongoing between companies that were working on mRNA vaccines during the pandemic, a merger agreement between two of them – BioNTech and CureVac ...
Regulatory agencies are offering more flexibility when it comes to viral clearance strategies, but this must be aligned with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results